Rituximab maintenance after initial treatment for marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a maintenance therapy with rituximab (a targeted antibody) can help prevent relapse after initial treatment with lenalidomide and rituximab (R2) in people with newly diagnosed marginal zone lymphoma who cannot have standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have marginal zone lymphoma (a type of slow-growing lymphoma) that has not been treated yet with systemic therapy.
- Your lymphoma should have a protein called CD20 on its cells (this is typical for marginal zone lymphoma).
- You are not able to undergo or do not want standard chemotherapy.
- You have at least one tumor that can be measured by scans or exam.
- You are in good enough health to be up and about for at least half the day (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as a first treatment for people with advanced marginal zone lymphoma. The goal is to see if this combination can help control the cancer without the need for chemotherapy.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This trial tests an oral medication called orelabrutinib as a follow-up treatment after initial therapy for marginal zone lymphoma that hasn't been treated yet. The goal is to see if it helps keep the lymphoma from coming back.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
This trial tests a new combination of two drugs (orelabrutinib and rituximab) compared to the standard R-CVP chemotherapy for people with newly diagnosed marginal zone lymphoma. The goal is to see which approach works better and has fewer side effects.
Hear when a new Marginal Zone Lymphoma(MZL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.